Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases.
Business Of Biotech · 31 minutes · 10 months ago
Running Interference: RNAi with Silence Therapeutics' Craig Tooman
Life Sciences Connect
Life Sciences Connect explores the big issues, the emerging trends and the cutting edge innovations that are shaping the Life Sciences industry. Each month, we will connect with industry experts and leaders from the Biotech, Pharmaceutical and Medical Devices industries to discus...
Explore Life Sciences
The life sciences industry is one of the fastest-growing communities in the world and we aim to shine a light on some amazing personalities. A monthly podcast where multiple members of the life science industry come together to explore and discuss opinions, developments and share...
Management Information Science
The MIS Podcast blends Technology and Business to help professionals learn more about common and up and coming technologies.
Mind Tap with Alternative Therapeutics
A psychoeducational podcast featuring therapists Britney Cirullo, Chase Harshbarger, and Olivia Clark from Alternative Therapeutics, a counseling practice in northeast Ohio. Episodes include tips and tricks to optimize mental wellness and dive deep into a variety of therapies suc...
All of us rant. All of us rage. All of us have beliefs that we communicate through anger and hatred. But here the hate simmers down from the boiling point. Here the happenings of the world are explored and addressed, viewed through the lens of art, stillness, and quietude. H...
Andy and Austin (and others?) donate (for tax purposes) recorded interpersonal interactions to the general public.